Compare ATMU & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATMU | SYRE |
|---|---|---|
| Founded | 1958 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.0B |
| IPO Year | 2023 | 2015 |
| Metric | ATMU | SYRE |
|---|---|---|
| Price | $63.98 | $64.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $58.25 | ★ $77.78 |
| AVG Volume (30 Days) | ★ 1.4M | 898.2K |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.35% | N/A |
| EPS Growth | ★ 12.61 | N/A |
| EPS | ★ 2.50 | N/A |
| Revenue | ★ $1,764,300,000.00 | N/A |
| Revenue This Year | $15.00 | N/A |
| Revenue Next Year | $5.13 | N/A |
| P/E Ratio | $25.39 | ★ N/A |
| Revenue Growth | ★ 5.67 | N/A |
| 52 Week Low | $31.68 | $12.04 |
| 52 Week High | $66.50 | $75.00 |
| Indicator | ATMU | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 63.10 | 80.96 |
| Support Level | $63.04 | $15.23 |
| Resistance Level | $66.25 | N/A |
| Average True Range (ATR) | 1.90 | 4.11 |
| MACD | 0.78 | 1.44 |
| Stochastic Oscillator | 96.76 | 66.69 |
Atmus Filtration Technologies Inc manufactures filtration products for on-highway commercial vehicles and off-highway agriculture, construction, mining, and power generation vehicles and equipment. The company designs and manufactures Developed filtration products, principally under the Fleetguard brand, that enable lower emissions and provide asset protection. The company designs, manufactures, and sells filters, coolants, and chemical products. The company offers products including air filtration, coolants and chemicals, crankcase ventilation, fuel filtration, fuel cells, lube filtration, and others.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.